Advances in pharmaceutical Co-crystal screening: Effective Co-crystal screening through structural resemblance

G. Springuel, K. Robeyns, T. Leyssens, B. Norberg, J. Wouters

Research output: Contribution to journalArticle

Abstract

Co-crystal screening was applied under the assumption that two molecules having relatively similar chemical structures are likely to form co-crystals with identical coformers, in an attempt to improve co-crystal screening efficiency. Piracetam and Levetiracetam were used as model compounds. Both molecules are racetam compounds and have a relatively similar molecular structure. Eleven co-crystals of Piracetam have been described in the literature using ten different acids. These ten acids were selected as potential coformer candidates for the preparation of Levetiracetam co-crystals. Four co-crystals of Levetiracetam were successfully identified by solvent drop and neat grinding: Levetiracetam-d-tartaric acid 1:1 (LDTA), Levetiracetam-R/S-mandelic acid 1:1 (L(RS)MA), Levetiracetam-S-mandelic acid 1:1 (LSMA), and Levetiracetam-2,4- dihyroxybenzoic acid 1:1 (L2,4DHBA). The overall success rate of 40% shows the usefulness of the presented approach. Structural investigation shows the increased success rate to most likely be due to the proficiency of two similar molecules to share the same driving force for assembling multicomponent systems with similar coformers.
Original languageEnglish
Pages (from-to)475-484
Number of pages10
JournalCrystal Growth and Design
Volume12
Issue number1
DOIs
Publication statusPublished - 1 Jan 2012

Fingerprint

etiracetam
Drug products
Screening
screening
Crystals
acids
Acids
Pharmaceutical Preparations
crystals
Piracetam
Molecules
molecules
grinding
assembling
Molecular structure
molecular structure

Cite this

@article{c944e7035975404dbdef764d10603df1,
title = "Advances in pharmaceutical Co-crystal screening: Effective Co-crystal screening through structural resemblance",
abstract = "Co-crystal screening was applied under the assumption that two molecules having relatively similar chemical structures are likely to form co-crystals with identical coformers, in an attempt to improve co-crystal screening efficiency. Piracetam and Levetiracetam were used as model compounds. Both molecules are racetam compounds and have a relatively similar molecular structure. Eleven co-crystals of Piracetam have been described in the literature using ten different acids. These ten acids were selected as potential coformer candidates for the preparation of Levetiracetam co-crystals. Four co-crystals of Levetiracetam were successfully identified by solvent drop and neat grinding: Levetiracetam-d-tartaric acid 1:1 (LDTA), Levetiracetam-R/S-mandelic acid 1:1 (L(RS)MA), Levetiracetam-S-mandelic acid 1:1 (LSMA), and Levetiracetam-2,4- dihyroxybenzoic acid 1:1 (L2,4DHBA). The overall success rate of 40{\%} shows the usefulness of the presented approach. Structural investigation shows the increased success rate to most likely be due to the proficiency of two similar molecules to share the same driving force for assembling multicomponent systems with similar coformers.",
author = "G. Springuel and K. Robeyns and T. Leyssens and B. Norberg and J. Wouters",
note = "Copyright 2012 Elsevier B.V., All rights reserved.",
year = "2012",
month = "1",
day = "1",
doi = "10.1021/cg201291k",
language = "English",
volume = "12",
pages = "475--484",
journal = "Crystal Growth and Design",
issn = "1528-7483",
publisher = "American Chemical Society",
number = "1",

}

Advances in pharmaceutical Co-crystal screening : Effective Co-crystal screening through structural resemblance. / Springuel, G.; Robeyns, K.; Leyssens, T.; Norberg, B.; Wouters, J.

In: Crystal Growth and Design, Vol. 12, No. 1, 01.01.2012, p. 475-484.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Advances in pharmaceutical Co-crystal screening

T2 - Effective Co-crystal screening through structural resemblance

AU - Springuel, G.

AU - Robeyns, K.

AU - Leyssens, T.

AU - Norberg, B.

AU - Wouters, J.

N1 - Copyright 2012 Elsevier B.V., All rights reserved.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Co-crystal screening was applied under the assumption that two molecules having relatively similar chemical structures are likely to form co-crystals with identical coformers, in an attempt to improve co-crystal screening efficiency. Piracetam and Levetiracetam were used as model compounds. Both molecules are racetam compounds and have a relatively similar molecular structure. Eleven co-crystals of Piracetam have been described in the literature using ten different acids. These ten acids were selected as potential coformer candidates for the preparation of Levetiracetam co-crystals. Four co-crystals of Levetiracetam were successfully identified by solvent drop and neat grinding: Levetiracetam-d-tartaric acid 1:1 (LDTA), Levetiracetam-R/S-mandelic acid 1:1 (L(RS)MA), Levetiracetam-S-mandelic acid 1:1 (LSMA), and Levetiracetam-2,4- dihyroxybenzoic acid 1:1 (L2,4DHBA). The overall success rate of 40% shows the usefulness of the presented approach. Structural investigation shows the increased success rate to most likely be due to the proficiency of two similar molecules to share the same driving force for assembling multicomponent systems with similar coformers.

AB - Co-crystal screening was applied under the assumption that two molecules having relatively similar chemical structures are likely to form co-crystals with identical coformers, in an attempt to improve co-crystal screening efficiency. Piracetam and Levetiracetam were used as model compounds. Both molecules are racetam compounds and have a relatively similar molecular structure. Eleven co-crystals of Piracetam have been described in the literature using ten different acids. These ten acids were selected as potential coformer candidates for the preparation of Levetiracetam co-crystals. Four co-crystals of Levetiracetam were successfully identified by solvent drop and neat grinding: Levetiracetam-d-tartaric acid 1:1 (LDTA), Levetiracetam-R/S-mandelic acid 1:1 (L(RS)MA), Levetiracetam-S-mandelic acid 1:1 (LSMA), and Levetiracetam-2,4- dihyroxybenzoic acid 1:1 (L2,4DHBA). The overall success rate of 40% shows the usefulness of the presented approach. Structural investigation shows the increased success rate to most likely be due to the proficiency of two similar molecules to share the same driving force for assembling multicomponent systems with similar coformers.

UR - http://www.scopus.com/inward/record.url?scp=84855404945&partnerID=8YFLogxK

U2 - 10.1021/cg201291k

DO - 10.1021/cg201291k

M3 - Article

VL - 12

SP - 475

EP - 484

JO - Crystal Growth and Design

JF - Crystal Growth and Design

SN - 1528-7483

IS - 1

ER -